Coronavirus Disease 2019 (COVID-19) Pandemic Impact on Clinical Trials

Coronavirus Disease 2019 (COVID-19) Pandemic Impact on Clinical Trials

Summary

This PowerPoint based report gives an important expert analysis on how COVID-19 is impacting clinical trials and the potential move toward decentralized clinical trials. Findings are based on a survey conducted with 150 respondents from around the world that belonged to Pharma/Biotech, Government/Academic Institutions, CROs, CMOs, or other contract service providers.

The report includes -

• Background, Objectives and Designs.
• Primary Concerns, which include business concerns, clinical trial concerns for decentralized clinical trials and addressing trial disruption.
• Movement Toward Decentralized Trials, including pre and post pandemic decentralized clinical trials use, future movement toward using decentralized clinical trials and cost comparison.
• Challenges Facing Decentralized Trials, which explores the biggest challenges and changes that are anticipated for decentralized clinical trials.

Scope

• A total of 150 the publisher's Pharma clients and prospects from the around the world participated in the seven-minute survey, which was fielded from June 4, 2020 to June 22, 2020.
• This report includes and is based around industry opinions on COVID-19’s impact on clinical trials and the use of decentralized clinical trials.

Reasons to Buy

• Understand companies’ primary concerns about the COVID-19 pandemic.
• Determine the impact of COVID-19 to date on clinical trials.
• Assess companies’ future plans to use decentralized clinical trials.
• Track changes to clinical trial strategy and attitudes.